Os peptídeos hormonais vegetais, que vêm sendo caracterizados em plantas desde a década de 90, podem estar relacionados com defesa, reprodução, crescimento e desenvolvimento de plantas. O peptídeo RALF (Rapid Alkalinization Factor), ubíquo no reino vegetal, está envolvido com o desenvolvimento de plantas. Em arabidopsis há 37 genes que codificam peptídeos RALF (AtRALFs). A isoforma mais estudada é a AtRALF1, a qual regula de maneira negativa a expansão celular, inibindo o crescimento de raiz primária e o alongamento de hipocótilo quando aplicado exogenamente. Recentemente, demonstrou-se a existência de uma relação antagônica entre AtRALF1 e a via de brassinosteróides (BRs) no desenvolvimento de raízes. Quando mutantes da via de sinalização do BR foram avaliados quanto a sua resposta ao peptídeo AtRALF1, descobriu-se que mutantes para o receptor quinase1 associado ao BRI1 (bak1) são insensíveis a AtRALF1. Experimentos utilizando o sistema de duplo híbrido em levedura, a co-imunoprecipitação e a indução de genes marcadores em mutantes bak1 foram realizados e confirmaram o envolvimento da proteína BAK1 na percepção do peptídeo. Plantas transgênicas que superexpressam AtRALF1 apresentam um fenótipo semi-anão, no entanto, quando as mesmas foram cruzadas com o mutante bak1, suas progênies apresentaram um fenótipo similar ao de plantas selvagens. Ainda, quando plantas deste cruzamento foram novamente cruzadas com plantas selvagens, plantas com fenótipo semi-anão foram observadas na prole. Ensaios de ligação usando o peptídeo AtRALF1 marcado com éster de acridínio foram realizados e mostraram que em mutantes bak1, a ligação do AtRALF1 é menor em aproximadamente 30% quando comparada com plantas selvagens. Os dados obtidos mostram que a proteína BAK1 interage fisicamente com o AtRALF1, está envolvida na percepção do peptídeo, é essencial para a inibição do crescimento da raiz primária causada pelo AtRALF1 e é necessária para a indução dos genes responsivos ao AtRALF1. / The plant peptides, which have been characterized in plants since the 90\'s, can be related to defense, reproduction, growth and development of plants. The RALF (Rapid Alkalinization Factor) peptide, ubiquitous in the plant kingdom, is related to the development of plants. In arabidopsis plants, there are 37 genes encoding RALF peptides (AtRALFs). AtRALF1 is the most studied isoform, which negatively regulate cell expansion, inhibiting primary root growth and hypocotyl elongation when it is applied exogenously. Recently, an antagonistic relationship between AtRALF1 and the brassinosteroids (BRs) to control root development had been demonstrated. When the response of mutants related to the BR signaling pathway to AtRALF1 peptide was investigated, it was found that mutants lacking the BRI1-associated receptor kinase1 (bak1) are insensitive to AtRALF1. Experiments using the two-hybrid system in yeast, co-immunoprecipitation, and the induction of marker genes in bak1 mutants were carried out, and confirmed the involvement of the BAK1 protein in the perception of AtRALF1 peptide. Transgenic plants overexpressing AtRALF1 are semi-dwarf. However, when those transgenic plants were crossed with bak1 mutant, their progeny showed a wild-type phenotype. Besides, when plants from this progeny were crossed again with wild-type plants, semi-dwarf phenotype plants were obtained in the offspring. Binding assays using AtRALF1 labeled with acridinium-ester were performed, and showed that in bak1 mutants, the AtRALF1 binding was reduced approximately 30% when compared to wild-type plants. All data indicate that BAK1 protein interacts physically with AtRALF1, it\'s involved with the peptide perception, essential for the primary root growth inhibition caused by AtRALF1, and required to the induction of genes responsive to AtRALF1.

Os peptídeos hormonais vegetais, que vêm sendo caracterizados em plantas desde a década de 90, podem estar relacionados com defesa, reprodução, crescimento e desenvolvimento de plantas. O peptídeo RALF (Rapid Alkalinization Factor), ubíquo no reino vegetal, está envolvido com o desenvolvimento de plantas. Em arabidopsis há 37 genes que codificam peptídeos RALF (AtRALFs). A isoforma mais estudada é a AtRALF1, a qual regula de maneira negativa a expansão celular, inibindo o crescimento de raiz primária e o alongamento de hipocótilo quando aplicado exogenamente. Recentemente, demonstrou-se a existência de uma relação antagônica entre AtRALF1 e a via de brassinosteróides (BRs) no desenvolvimento de raízes. Quando mutantes da via de sinalização do BR foram avaliados quanto a sua resposta ao peptídeo AtRALF1, descobriu-se que mutantes para o receptor quinase1 associado ao BRI1 (bak1) são insensíveis a AtRALF1. Experimentos utilizando o sistema de duplo híbrido em levedura, a co-imunoprecipitação e a indução de genes marcadores em mutantes bak1 foram realizados e confirmaram o envolvimento da proteína BAK1 na percepção do peptídeo. Plantas transgênicas que superexpressam AtRALF1 apresentam um fenótipo semi-anão, no entanto, quando as mesmas foram cruzadas com o mutante bak1, suas progênies apresentaram um fenótipo similar ao de plantas selvagens. Ainda, quando plantas deste cruzamento foram novamente cruzadas com plantas selvagens, plantas com fenótipo semi-anão foram observadas na prole. Ensaios de ligação usando o peptídeo AtRALF1 marcado com éster de acridínio foram realizados e mostraram que em mutantes bak1, a ligação do AtRALF1 é menor em aproximadamente 30% quando comparada com plantas selvagens. Os dados obtidos mostram que a proteína BAK1 interage fisicamente com o AtRALF1, está envolvida na percepção do peptídeo, é essencial para a inibição do crescimento da raiz primária causada pelo AtRALF1 e é necessária para a indução dos genes responsivos ao AtRALF1. / The plant peptides, which have been characterized in plants since the 90\'s, can be related to defense, reproduction, growth and development of plants. The RALF (Rapid Alkalinization Factor) peptide, ubiquitous in the plant kingdom, is related to the development of plants. In arabidopsis plants, there are 37 genes encoding RALF peptides (AtRALFs). AtRALF1 is the most studied isoform, which negatively regulate cell expansion, inhibiting primary root growth and hypocotyl elongation when it is applied exogenously. Recently, an antagonistic relationship between AtRALF1 and the brassinosteroids (BRs) to control root development had been demonstrated. When the response of mutants related to the BR signaling pathway to AtRALF1 peptide was investigated, it was found that mutants lacking the BRI1-associated receptor kinase1 (bak1) are insensitive to AtRALF1. Experiments using the two-hybrid system in yeast, co-immunoprecipitation, and the induction of marker genes in bak1 mutants were carried out, and confirmed the involvement of the BAK1 protein in the perception of AtRALF1 peptide. Transgenic plants overexpressing AtRALF1 are semi-dwarf. However, when those transgenic plants were crossed with bak1 mutant, their progeny showed a wild-type phenotype. Besides, when plants from this progeny were crossed again with wild-type plants, semi-dwarf phenotype plants were obtained in the offspring. Binding assays using AtRALF1 labeled with acridinium-ester were performed, and showed that in bak1 mutants, the AtRALF1 binding was reduced approximately 30% when compared to wild-type plants. All data indicate that BAK1 protein interacts physically with AtRALF1, it\'s involved with the peptide perception, essential for the primary root growth inhibition caused by AtRALF1, and required to the induction of genes responsive to AtRALF1.

Cancer is one of the leading causes of death in the world, often due to failed treatments because of drug resistance. Treatment is difficult as resistance is hard to detect before treatment and can develop during treatment. The fluorometric microculture cytotoxicity assay (FMCA) is a reliable, rapid method for testing drug cytotoxicity but requires large cell samples, which can be challenging to obtain. Patient-derived cancer cells (PDC) have proven challenging to culture in monolayer models, but recent studies have shown the possibility of using tumoroids. Tumoroids are three-dimensional models where cells are grown in basement membrane matrix hydrogel, allowing scaffold growth like in vivo tumors. This study aimed to culture colorectal PDC in the form of tumoroids, transfecting them, and examine cell cycle and tumor resistance for 5-Fluorouracil, Oxaliplatin and Irinotecan. Cells were deposited in gels with medium mimicking in vivo conditions, supporting growth and allowing extracellular signaling. The study succeeded in culturing both untransfected and transfected cells, resulting in cells expanding 48 and 42 times, respectively. Cell cycle remained unchanged. No changes were observed in 5-Fluorouracil, but a change was seen in transfected cells at passage 3 with oxaliplatin. The cells showed a 22% difference in survival indexes compared to naïve cells. Changes were seen in Irinotecan’s half maximal inhibitory concentration (IC50); all cell passage IC50 values differed >15.17 µM (p-value 0.0184). In conclusion, PDC can be cultured as tumoroids, but more studies are needed to determine if the model can generate reliable results representing PDC regarding tumor resistance.

The engraftment of haemopoietic stem/progenitor cells (HSPCs) from umbilical cord blood (UCB) into adult recipients, although advantageous in terms of sourcing units, the decreased need to match donor and recipient and reduced risk of graft versus host disease (GvHD), is delayed compared to grafts using HSPCs from mobilised peripheral blood (MPB) or bone marrow (BM). One reason for this is the limited number of HSPCs (CD34+/CD133+ cells) in a unit of UCB compared to MPB or BM. The CXCR4-CXCL12 axis is widely recognised as a key player in the bone marrow homing, retention, and engraftment of HSPCs. The aim of this thesis was to investigate whether the engraftment of HSPCs from UCB into the bone marrow could be improved. Firstly, a novel in vitro 3D time-lapse chemotaxis assay to assess the homing capacity of human UCB CD133+ HSPCs, towards the chemokine CXCL12 was developed. One advantage of this assay was that it distinguished cell chemotaxis from chemokinesis and allowed these parameters to be quantified. Human UCB CD133+ HSPC chemotaxis towards CXCL12 was inhibited by the CXCR4 antagonist, AMD3100. Importantly, the presence of CXCL12 or AMD3100 had no affect on cell chemokinesis. To complement the in vitro chemotaxis assay, a short term in vivo homing assay in NSG mice was successfully established. The effect of siRNA silencing of the CXCR4 co-receptor, CD164, which is also expressed on CD133+ HSPCs, on cell migratory and homing ability was investigated. CD164 knock-down using siRNA in human UCB CD133+ HSPCs did not demonstrate an effect on homing to NSG bone marrow in vivo or chemotaxis to CXCL12 in vitro. However, homing to NSG mouse spleen was significantly reduced in cells silenced for CD164. Following this, an 8 day HSPC expansion system using nanofibre scaffolds (Nanex) and differing cytokines was investigated. These serum and feeder free conditions yielded a significant expansion of cells that retained CD133+CD34+ expression and their in vitro chemotactic ability to CXCL12. Time constraints did not permit the engrafting ability of these cells to be analysed in an in vivo HSC reconstitution assay that was initiated. However these studies will provide the basis to support future related research in this laboratory.

<p>The actin cytoskeleton is required for cell expansion and is implicated in cellular responses to the plant growth hormone auxin. However, the molecular and cellular mechanisms that coordinate auxin signaling, cytoskeletal remodeling, and cell expansion are poorly understood. Previous studies have examined actin cytoskeleton responses to long-term auxin treatment, but plants respond to auxin over short timeframes, and growth changes within minutes of exposure to the hormone. To correlate actin arrays with degree of cell expansion, we used quantitative imaging tools to establish a baseline of actin organization, as well as of individual filament behaviors in root epidermal cells under control conditions and after treatment with a known inhibitor of root growth, the auxin indole-3-acetic acid (IAA). We found that cell length was highly predictive of actin array in control roots, and that short-term IAA treatment stimulated denser, more longitudinal, and more parallel arrays by inducing filament unbundling within minutes. By demonstrating that actin filaments were more “organized” after a treatment that stopped elongation, we show there is no direct relationship between actin organization and cell expansion and refute the hypothesis that “more organized” actin universally correlates with more rapidly growing root cells. The plasma membrane-bound auxin transporter AUXIN RESISTANT 1 (AUX1) has previously been shown necessary for archetypal short-term root growth inhibition in the presence of IAA. Although AUX1 was not previously suspected of being upstream of cytoskeletal responses to IAA, we used <i>aux1</i>mutants to demonstrate that AUX1 is necessary for the full complement of actin rearrangements in response to auxin, and that cytoplasmic auxin in the form of the membrane permeable auxin 1‑naphthylacetic acid (NAA) is sufficient to stimulate a partial actin response. Together, these results are the first to quantitate actin cytoskeleton response to short-term auxin treatments and demonstrate that AUX1 is necessary for short-term actin remodeling.</p>

As células estromais mesenquimais (CMMs) se tornaram de grande interesse para a terapia celular devido ao seu potencial de se diferenciar e reconstituir tecidos especializados. Mais recentemente, este interesse tem aumentado significativamente devido à descoberta de que as CMMs são capazes de secretar uma infinidade de mediadores para estimular a regeneração in situ de tecidos lesados. Dessa forma, CMMs podem ser consideradas tanto como um produto terapêutico em si, quanto uma biofábrica de diversas proteínas relevantes do ponto de vista terapêutico. Para atender a estas crescentes demandas, ambas as aplicações requerem o desenvolvimento de processos de expansão celular com alto rendimento, sob condições de cultivo definidas, reprodutíveis, escalonáveis, permitindo a obtenção de produtos com adequada identidade, potência, pureza, segurança e viáveis economicamente. Frente ao exposto, este trabalho teve como objetivos principais o estabelecimento de um processo de expansão de CMMs baseado em biorreatores e a caracterização do secretoma destas células visando aplicações terapêuticas. Para isto, a expansão de CMMs do cordão umbilical (MCUs) foi realizada em frascos multicamadas (MC) e nos biorreatores de leito fixo (LF), tanque agitado com microcarregadores (TA) e fibrasocas (FO). Os resultados mostraram que a taxa de proliferação específica das células foi maior (< tempo de duplicação) no biorreator de FO (36,8 ± 1,7 horas), bem como o fator de expansão (9,8 ± 1,0) e a eficiência na recuperação celular (100%). Um nível similar de produção celular foi observado para o TA, MC e LF com elevado fator de expansão celular (8,8 ± 0,39, 8,7 ± 0,90, 6,9 ± 1,3, respectivamente). No entanto, em termos de eficiência na recuperação celular (%), LF apresentou a menor taxa de recuperação dentre todos os sistemas (18% (± 0,77)), acompanhado pelo TA (61% (± 15,7)). As células mantiveram suas características imunofenotípicas e o potencial de diferenciação em adipócitos, osteócitos e condrócitos em todos os sistemas de cultivo avaliados. Foi também realizada a análise de custos (COG) e avaliação da viabilidade econômica para produção de CMMs visando tratamento da doença do enxerto contra o hospedeiro (DECH) em escala comercial, utilizando os sistemas de cultivo avaliados experimentalmente sob diferentes estratégias de reembolso. Apesar dos resultados experimentais satisfatórios para o biorreator FO, o COG revelou que este sistema tem o maior custo devido aos elevados custos dos consumíveis requeridos e do custo do equipamento. O frasco MC foi considerado como a tecnologia mais rentável e robusta no cenário avaliado e o biorreator TA obteve a segunda posição. O biorreator TA foi escolhido como o mais adequado analisando de maneira conjunta os dados experimentais obtidos, a análise dos custos dos diferentes sistemas de cultivo e a escalonabilidade de cada sistema. Assim, esse biorreator foi eficientemente utilizado para o cultivo de MCUs em condições isentas de SFB e xenoantígenos, sendo possível a produção de uma grande quantidade de células, representando um passo importante no desenvolvimento de um bioprocesso em conformidade com as normas das agências regulatórias. Por fim, com a análise do secretoma das CMMs por espectrometria de massas foi possível a identificação de uma gama enorme de proteínas interessantes (aprox. 2400) envolvidas em importantes processos biológicos. O futuro monitoramento dessas proteínas em biorreatores poderá representar um método inovador e original de produção de produtos livres de células para uso na terapia celular. / Mesenchymal stem/stromal cells (MSC) have become of great interest for cell therapy because of its potential to differentiate and reconstitute specialized tissues. More recently, such interest has significantly increased due to the discovery that MSC are capable of secreting a plethora of mediators to stimulate the in situ regeneration of injured tissues. Thus, MSC can be considered as a therapeutic product itself and as a biofactory of various relevant therapeutic proteins. To meet these increasing demands, both applications require the development of high-yield, reproducible, scalable and cost-effective bioprocesses under defined culture conditions, obtaining products with proper identity, purity and safety. Based on these, the main goal of this work was the establishment of a MSC expansion process based on bioreactors and secretome characterization of these cells targeting therapeutic applications. The MSC expansion was performed using multi-layered flasks (ML) and fixed bed (PB), stirred tank (STR) and hollow fiber (HF) bioreactors. The results showed that the proliferation rate of the cells was higher (< doubling time) in the HF bioreactor (36.8 ± 1.7 hours), as well as the expansion fold-increase (9.8±1.0) and harvesting efficiency (100%). A similar level of cell production was observed for STR, ML and PB with high fold-increase (8.8±0.39, 8.7±0.90, 6.9±1.3, respectively). However, in terms of harvesting efficiency (%), PB bioreactor presented the lowest retrieval rate across all the technologies (18% (±0.77)), followed by STR (61% (±15.7)). The cells retained their functional properties after culture in all the culture systems evaluated. This study was then extended through the use of a bioprocess economics tool for the evaluation of the economic feasibility of producing MSC-based treatment for acute graft vs. host disease (aGvHD) at commercial scale, using the culture systems experimentally evaluated under different reimbursement strategies. Despite the advantageous experimental results of HF bioreactors, the COG analysis has revealed that this is the least cost effective cell culture system to be used, due to its high consumable and equipment costs. ML flasks ranked first as the most cost effective and robust technology in this scenario and microcarrier-based technologies (STR) ranked in second position. The STR bioreactor was chosen as the most suitable for MSC expansion analyzing the experimental data, COG analysis and scalability of each culture system. Thus, STR bioreactor was efficiently tested for MSC expansion under serum and xeno-free conditions and it was possible to produce a large amount of cells. The development of a scalable microcarrier-based stirred culture system using xeno-free culture medium that suits the intrinsic features of UCM-derived MSC represents an important step towards a GMP compliant large-scale production platform for these promising cell therapy candidates. Finally, with the MSC secretome analysis by mass spectrometry it was possible to identify a wide range of interesting proteins (approx. 2400) involved in important biological processes. The future monitoring of these proteins in bioreactors may represent a novel and unique method of producing cell-free products for use in cellular therapy.

L'essor des thérapies régénératives au cours des 10 dernières années a entraîné un effort de recherche important, mais l'obtention des cellules souches humaines en quantité suffisante reste cependant encore problématique, notamment concernant les cellules souches mésenchymateuses (CSM). Ces travaux ont donc mis en œuvre une approche à la croisée de la biologie et du génie des procédés afin d'identifier les verrous limitant la croissance des CSM. L'étude des méthodes d'intensification de culture a été entreprise grâce à l'utilisation de microporteurs et d'une plateforme de minibioréacteurs de 200~mL. Puis le développement d'un milieu de culture sans sérum a été testé dans le but de maximiser la croissance cellulaire dans des conditions biochimiques contrôlées. Les CSM humaines en tant que modèle type en thérapie cellulaire ont été démontrées comme extrêmement sensibles aux phases de congélation/décongélation, aux variations de température, à un vieillissement prématuré et nécessitant un milieu de culture complexe riche en facteurs de croissance et d'adhérence. Suite à cette étude, plusieurs écueils pourront être évités lors de la montée en échelle d'un procédé de culture de CSM afin d'intégrer leurs paramètres biologiques intrinsèques aux paramètres d'ingénierie des bioréacteurs (transfert de chaleur, contraintes hydrodynamiques, surface d'adhérence) / Progress in regenerative medicines over the past ten years have led to an important research mobilisation, but obtaining a sufficient amount of human stem cells remains nonetheless problematic, especially for mesenchymal stem cells (MSC). Hence, this work developed an approach coupling biology and process engineering to identify barriers limiting MSC growth. The study of scaled-up amplification methods was performed using microcarriers and a 200~mL minibioreactors platform. In order to maximise MSC growth in a biochemically controlled environment, a serum free medium development was tested as well. Human MSC as model cell type for cellular therapies have thus been demonstrated as extremely sensitive to freeze/thaw cycles, temperature variations, subject to premature aging and needing a complex medium enriched in multiple growth and adherence factors. Following this study, several pitfalls might be avoided during MSC process scale-up by integrating the cells biology into the bioreactors' process engineering parameters (heat transfer, hydrodamic stress, adhesion surface)

As células estromais mesenquimais (CMMs) se tornaram de grande interesse para a terapia celular devido ao seu potencial de se diferenciar e reconstituir tecidos especializados. Mais recentemente, este interesse tem aumentado significativamente devido à descoberta de que as CMMs são capazes de secretar uma infinidade de mediadores para estimular a regeneração in situ de tecidos lesados. Dessa forma, CMMs podem ser consideradas tanto como um produto terapêutico em si, quanto uma biofábrica de diversas proteínas relevantes do ponto de vista terapêutico. Para atender a estas crescentes demandas, ambas as aplicações requerem o desenvolvimento de processos de expansão celular com alto rendimento, sob condições de cultivo definidas, reprodutíveis, escalonáveis, permitindo a obtenção de produtos com adequada identidade, potência, pureza, segurança e viáveis economicamente. Frente ao exposto, este trabalho teve como objetivos principais o estabelecimento de um processo de expansão de CMMs baseado em biorreatores e a caracterização do secretoma destas células visando aplicações terapêuticas. Para isto, a expansão de CMMs do cordão umbilical (MCUs) foi realizada em frascos multicamadas (MC) e nos biorreatores de leito fixo (LF), tanque agitado com microcarregadores (TA) e fibrasocas (FO). Os resultados mostraram que a taxa de proliferação específica das células foi maior (< tempo de duplicação) no biorreator de FO (36,8 ± 1,7 horas), bem como o fator de expansão (9,8 ± 1,0) e a eficiência na recuperação celular (100%). Um nível similar de produção celular foi observado para o TA, MC e LF com elevado fator de expansão celular (8,8 ± 0,39, 8,7 ± 0,90, 6,9 ± 1,3, respectivamente). No entanto, em termos de eficiência na recuperação celular (%), LF apresentou a menor taxa de recuperação dentre todos os sistemas (18% (± 0,77)), acompanhado pelo TA (61% (± 15,7)). As células mantiveram suas características imunofenotípicas e o potencial de diferenciação em adipócitos, osteócitos e condrócitos em todos os sistemas de cultivo avaliados. Foi também realizada a análise de custos (COG) e avaliação da viabilidade econômica para produção de CMMs visando tratamento da doença do enxerto contra o hospedeiro (DECH) em escala comercial, utilizando os sistemas de cultivo avaliados experimentalmente sob diferentes estratégias de reembolso. Apesar dos resultados experimentais satisfatórios para o biorreator FO, o COG revelou que este sistema tem o maior custo devido aos elevados custos dos consumíveis requeridos e do custo do equipamento. O frasco MC foi considerado como a tecnologia mais rentável e robusta no cenário avaliado e o biorreator TA obteve a segunda posição. O biorreator TA foi escolhido como o mais adequado analisando de maneira conjunta os dados experimentais obtidos, a análise dos custos dos diferentes sistemas de cultivo e a escalonabilidade de cada sistema. Assim, esse biorreator foi eficientemente utilizado para o cultivo de MCUs em condições isentas de SFB e xenoantígenos, sendo possível a produção de uma grande quantidade de células, representando um passo importante no desenvolvimento de um bioprocesso em conformidade com as normas das agências regulatórias. Por fim, com a análise do secretoma das CMMs por espectrometria de massas foi possível a identificação de uma gama enorme de proteínas interessantes (aprox. 2400) envolvidas em importantes processos biológicos. O futuro monitoramento dessas proteínas em biorreatores poderá representar um método inovador e original de produção de produtos livres de células para uso na terapia celular. / Mesenchymal stem/stromal cells (MSC) have become of great interest for cell therapy because of its potential to differentiate and reconstitute specialized tissues. More recently, such interest has significantly increased due to the discovery that MSC are capable of secreting a plethora of mediators to stimulate the in situ regeneration of injured tissues. Thus, MSC can be considered as a therapeutic product itself and as a biofactory of various relevant therapeutic proteins. To meet these increasing demands, both applications require the development of high-yield, reproducible, scalable and cost-effective bioprocesses under defined culture conditions, obtaining products with proper identity, purity and safety. Based on these, the main goal of this work was the establishment of a MSC expansion process based on bioreactors and secretome characterization of these cells targeting therapeutic applications. The MSC expansion was performed using multi-layered flasks (ML) and fixed bed (PB), stirred tank (STR) and hollow fiber (HF) bioreactors. The results showed that the proliferation rate of the cells was higher (< doubling time) in the HF bioreactor (36.8 ± 1.7 hours), as well as the expansion fold-increase (9.8±1.0) and harvesting efficiency (100%). A similar level of cell production was observed for STR, ML and PB with high fold-increase (8.8±0.39, 8.7±0.90, 6.9±1.3, respectively). However, in terms of harvesting efficiency (%), PB bioreactor presented the lowest retrieval rate across all the technologies (18% (±0.77)), followed by STR (61% (±15.7)). The cells retained their functional properties after culture in all the culture systems evaluated. This study was then extended through the use of a bioprocess economics tool for the evaluation of the economic feasibility of producing MSC-based treatment for acute graft vs. host disease (aGvHD) at commercial scale, using the culture systems experimentally evaluated under different reimbursement strategies. Despite the advantageous experimental results of HF bioreactors, the COG analysis has revealed that this is the least cost effective cell culture system to be used, due to its high consumable and equipment costs. ML flasks ranked first as the most cost effective and robust technology in this scenario and microcarrier-based technologies (STR) ranked in second position. The STR bioreactor was chosen as the most suitable for MSC expansion analyzing the experimental data, COG analysis and scalability of each culture system. Thus, STR bioreactor was efficiently tested for MSC expansion under serum and xeno-free conditions and it was possible to produce a large amount of cells. The development of a scalable microcarrier-based stirred culture system using xeno-free culture medium that suits the intrinsic features of UCM-derived MSC represents an important step towards a GMP compliant large-scale production platform for these promising cell therapy candidates. Finally, with the MSC secretome analysis by mass spectrometry it was possible to identify a wide range of interesting proteins (approx. 2400) involved in important biological processes. The future monitoring of these proteins in bioreactors may represent a novel and unique method of producing cell-free products for use in cellular therapy.

Le développement d’un organisme multicellulaire requière la coordination de la croissance, détermination tissulaire et différenciation cellulaire. Cependant, alors que les bases de la génétique de la morphogenèse ont été rigoureusement étudiées, le processus permettant la conversion de l’activité génétique en des structures biologiques complexes est bien moins compris. Chez Arabidopsis thaliana, les feuilles et fleurs initiés à partir du Méristème Apical Primaire (MAP) ont une expression génétique casi similaire. Toutefois, leur forme est considérablement différente dès les premières étapes de leur développement. Une compréhension de ce paradoxe requière avant tout de précisément quantifier la croissance dans toutes les dimensions de ces organes. Dans cet article, je présente une méthode de quantification spatio-temporelle complète de la croissance et de la prolifération des feuilles et des fleurs chez A. thaliana. En analysant des séries d’images confocales, j’en ai conclu que la différence morphologique observée entre feuilles et fleurs émerge principalement d’une asymétrie de la distribution de la croissance entre leurs côtés abaxial et adaxial, tôt dans leur développement. Je montre que le tissue contribuant principalement au développement des primordia est la couche 2 (L2) chez les feuilles et la couche 3 (L3) chez les fleurs. Mes résultats préliminaires démontrent que les premiers signes de l’initiation d’organes est un changement de distribution de la croissance, et non de la prolifération. Dans le futur, en appliquant, par exemple, cette méthodologie à l’étude de gènes de développement, il sera possible de finalement réconcilier la morphogenèse et la génétique de l’initiation des plantes. / The development of a multicellular organism requires the proper coordination of growth, pattern determination and cell differentiation. Still, while the genetic basis of morphogenesis has been extensively studied, the process converting gene activity into intricate biological shapes is less understood. In Arabidopsis thaliana, flowers and leaves, both initiated from the shoot apical meristem (SAM), have a very similar genetic expression profile. Yet, their shape differs considerably from early developmental stages. A full comprehension of this paradox requires an accurate quantification of cellular growth in those organs. In this paper, I am presenting a methodology for the complete spatio-temporal quantitative analysis of growth and proliferation of initiating leaves and flowers in wild type Arabidopsis thaliana. By analyzing time series of leaf and flower confocal images, I conclude that the morphological differences observed between flowers and leaves mainly arises from asymmetrical distributions of growth between their adaxial and abaxial sides during their initiation. I show that the tissue that mainly contributes to the development of early primordium is the layer 2 (L2) in leaves, and the layer 3 (L3) in flowers. My preliminary results also demonstrate that the first signs of organ initiation are a change in growth distribution, not cell proliferation. In the future, by applying this methodology, for example, to study morphogen reporter lines, it could finally bridge the gap between the morphogenesis and the genetics of plant initiation.

No description available.